Accentia

New lease of life for asthmatics by Accentia Biopharmaceuticals

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), through its specialty pharmaceuticals subsidiary, TEAMM Pharmaceuticals, Inc., has developed MD Turbo.// It is the first and only available product that transforms many of the most commonly prescribed metered dose inhalers (MDIs) into breath-activat...

Accentia announces investigational new drug application for Revimmune for refractory MS

... Revimmune. The FDA has indicated its support for accentia to submit an IND for a pivotal Phase 3 randomized ...ted that they support the proposed submission from accentia and that they are in overall agreement with the proposed design of the accentia clinical program. The Revimmune MS study will e...

Accentia in Medical Technology

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

...o significantly reduce morbidity is tremendous." accentia has received Fast Track status from the Food and D...trials_sinunase.php, or call 212-686-4100. About accentia Biopharmaceuticals, Inc. accentia Biopharmaceuticals, Inc. is a biopharmaceutical co...

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

...rchived on Accentia's website for 90 days. About accentia Biopharmaceuticals, Inc. accentia Biopharmaceuticals, Inc. and its subsidiaries (col...other factors that may cause the actual results of accentia to be materially different from historical results...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

... system. Biovest is a majority-owned subsidiary of accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its r...t the Company Web site at www.biovest.com. About accentia Biopharmaceuticals, Inc. accentia Biopharmaceuticals, Inc. and its subsidiaries (col...

Accentia in Biological News

SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma

... has an exclusive commercialization agreement with accentia Biopharmaceuticals. The Company believes that Sin...ssuming FDA approval. As previously announced, accentia has received Fast Track status from the Food and D...first therapy available to treat sufferers of CS. accentia Biopharmaceuticals is commercializing SinuTest for...